Candida auris | Fungal Diseases | CDC
Case Count Updated: July 14, 2017
Candida auris is an emerging fungus that presents a serious global health threat. Healthcare facilities in several countries have reported that
C. auris has caused severe illness in hospitalized patients. Some strains of
C. auris are resistant to all three major classes of antifungal drugs. This type of multidrug resistance has not been seen before in other species of
Candida. Also of concern,
C. auris can persist on surfaces in healthcare environments and spread between patients in healthcare facilities. CDC has developed
identification,
treatment, and
infection control recommendations to help prevent the spread of
C. auris.
CDC encourages all U.S. laboratory staff who identify
C. auris to notify their state or local public health authorities and CDC at
candidaauris@cdc.gov.
What's New?
Publications
CDC Publications:
- Tsay, S., et. al. Ongoing Transmission of Candida auris in Health Care Facilities — United States, June 2016–May 2017. MMWR, 2017, May 18.
- Berkow, et al. In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida auris. Antimicrob Agents Chemother. 2017 May 8.
- Vallabhaneni, S., et. al. Investigation of the first seven reported U.S. cases of Candida auris, a globally-emerging invasive fungus — United States, May 2013–August 2016 . MMWR, 2016, Nov 4.
- Lockhart, S., et al., Simultaneous emergence of multidrug resistant Candida auris on three continents confirmed by whole genome sequencing and epidemiological analyses. Clinical Infectious Dis, 2016, Oct 20.
Candida auris reported from other countries:
India
Israel
- Ben-Ami, R., et al., Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis, 2017. 23(2): p.195-203.
- Ben-Ami, R., et al., Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother, 2012. 56(5): p. 2518-23.
Japan
Kuwait
South Afria
South Korea
Spain
United Kingdom
Venezuela
Recommendations from other countries
Laboratory aspects of Candida auris
- Larkin, E., et al. The emerging pathogen Candida auris: Growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. Antimicrob Agents Chemother. 2017 Apr 24;61(5).
- Mizusawa, M., et al. Can a multi-drug resistant Candida auris be reliably identified in clinical microbiology laboratories? J. Clin. Microbiol, 2016, Nov 23.
- Sherry, L., et al., Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris. Emerg Infect Dis, 2017.23(2): p. 328-31.
Other publications
No hay comentarios:
Publicar un comentario